Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.53 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263363 | 0.87 | GPR119 (0.51) | GPR119TBK1FAAH | |
| SCHEMBL6803580 | 0.84 | GRIN2B (0.38) | GPR119TBK1TGFBR1 | |
| SCHEMBL390655 | 0.81 | TBK1 (0.46) | GPR119TBK1TGFBR1 | |
| SCHEMBL27747830 | 0.80 | GPR119 (0.49) | GPR119TBK1TGFBR1 | |
| SCHEMBL391077 | 0.80 | TBK1 (0.47) | GPR119TBK1TGFBR1 | |
| SCHEMBL391594 | 0.80 | GPR119 (0.51) | GPR119TBK1TGFBR1 | |
| SCHEMBL390779 | 0.80 | TBK1 (0.47) | GPR119TBK1TGFBR1 | |
| SCHEMBL387995 | 0.80 | GPR119 (0.47) | GPR119TBK1TGFBR1 | |
| SCHEMBL387040 | 0.80 | GPR119 (0.58) | GPR119 | |
| SCHEMBL389695 | 0.80 | GPR119 (0.47) | GPR119TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1341540-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | GPR119 316/4885TBK1 145/4885FAAH 4549/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | GPR119 316/4885TBK1 145/4885FAAH 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.